Genetic Technologies Limited (GENE)

NASDAQ: GENE · IEX Real-Time Price · USD
1.940
-0.050 (-2.51%)
At close: Feb 27, 2024, 3:57 PM
2.290
+0.350 (18.04%)
After-hours: Feb 27, 2024, 7:59 PM EST
-2.51%
Market Cap 7.70M
Revenue (ttm) 5.78M
Net Income (ttm) -8.67M
Shares Out 3.85M
EPS (ttm) -2.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 186,555
Open 1.960
Previous Close 1.990
Day's Range 1.835 - 2.000
52-Week Range 1.800 - 6.650
Beta 0.32
Analysts n/a
Price Target n/a
Earnings Date Mar 12, 2024

About GENE

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as ... [Read more]

Sector Healthcare
Founded 1989
Employees 60
Stock Exchange NASDAQ
Ticker Symbol GENE
Full Company Profile

Financial Performance

In 2023, GENE's revenue was 8.69 million, an increase of 27.83% compared to the previous year's 6.79 million. Losses were -11.75 million, 64.8% more than in 2022.

Financial numbers in AUD Financial Statements

News

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises...

7 weeks ago - GlobeNewsWire

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Mone...

Other symbols: BIVI
2 months ago - Accesswire

Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change

MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious...

2 months ago - GlobeNewsWire

GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious...

4 months ago - GlobeNewsWire

Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDA...

Other symbols: KSCPSNGX
5 months ago - Accesswire

GTG Signs Precision Medicine Pilot with Australia's Largest Private Hospital Network

MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serio...

5 months ago - GlobeNewsWire

Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE), and American Re...

Other symbols: AREC
5 months ago - Accesswire

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice

6 months ago - GlobeNewsWire

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, we...

6 months ago - GlobeNewsWire

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money R...

Other symbols: SXTP
6 months ago - Accesswire

Annual Results – Momentum Building on our Commercial Plans

MELBOURNE, Australia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wel...

6 months ago - GlobeNewsWire

Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the successful completion of an employer-sponsored heart disease fair in Kansas, United States.

Other symbols: CDIO
6 months ago - Business Wire

Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness and serious disease, advises ...

7 months ago - GlobeNewsWire

New Publication Validates geneType for Melanoma Risk Assessment

MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious...

10 months ago - GlobeNewsWire

Back-to-back Studies Validate geneType Breast Cancer Risk Test

MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and seriou...

1 year ago - GlobeNewsWire

Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-b...

1 year ago - GlobeNewsWire

Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious...

1 year ago - GlobeNewsWire

Genetic Technologies Announces $5 Million Registered Direct Offering

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-b...

1 year ago - GlobeNewsWire

GENE to Launch World's First Comprehensive Risk Test for Breast & Ovarian Cancer

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious ...

1 year ago - GlobeNewsWire

Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth

MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellne...

1 year ago - GlobeNewsWire

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wel...

1 year ago - GlobeNewsWire

Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wel...

1 year ago - GlobeNewsWire

Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / October 13, 2022 / RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based ...

1 year ago - Accesswire

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and seriou...

1 year ago - GlobeNewsWire

Genetic Technologies Provides Update on US Operations and Payer Engagement

MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in he...

1 year ago - GlobeNewsWire